Regulation of human papillomavirus gene expression by splicing and polyadenylation

Nature Reviews Microbiology

Volumn 11, Issue 4, 2013, Pages 239-251

  Johansson, Cecilia ^a   Schwartz, Stefan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MESSENGER RNA; PROTEIN E6; PROTEIN E7; RETINOBLASTOMA PROTEIN; VIRUS DNA;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; CANCER RISK; DNA REPLICATION; EXON; EXON SKIPPING; GENE EXPRESSION REGULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMEDIATE EARLY GENE; INTRON; LIFE CYCLE; NONHUMAN; PERSISTENT VIRUS INFECTION; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY SEQUENCE; REVIEW; RNA SPLICING; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; VIRUS GENE; VIRUS GENOME; WART VIRUS;

FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; POLYADENYLATION; RNA SPLICING; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84876418054     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2984     Document Type: Review

References (140)

1. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev. Cancer 2, 342-350 (2002).
2. Bernard, H. U. et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401, 70-79 (2010).
3. Bouvard, V. et al. A review of human carcinogens-part B: biological agents. Lancet Oncol. 10, 321-322 (2009).
4. Bosch, F. X., Lorincz, A., Munoz, N. & Meijer, C. J. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55, 244-265 (2002).
5. Walboomers, J. M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
6. Parkin, D. M., Bray, F. I. & Devesa, S. S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37 (Suppl. 8), 24-66 (2001).
7. Chow, L. T., Broker, T. R. & Steinberg, B. M. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 11 8, 422-449 (2010).
8. Stanley, M. A. Epithelial cell responses to infection with human papillomaviruses. Clin. Microbiol. Rev. 25, 215-222 (2012).
9. Doorbar, J. The papillomavirus life cycle. J. Clin. Virol. 32 (Suppl. 1), S7-S15 (2005).
10. Moody, C. A. & Laimins, L. A. Human papillomavirus oncoproteins: pathways to transformation. Nature Rev. Cancer 10, 550-560 (2010).
11. Bodily, J. & Laimins, L. A. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19, 33-29 (2011).
12. Stenlund, A. Initiation of DNA replication: lessons from viral initiator proteins-. Nature Rev. Mol. Cell Biol. 4, 777-785 (2003).
13. Münger, K. & Howley, P. Human papillomavirus immortalization and transformation functions. Virus Res. 89, 213-228 (2002).
14. Pim, D., Massimi, P. & Banks, L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15, 257-264 (1997).
15. Venuti, A. et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol. Cancer 10, 140 (2011).
16. DiMaio, D. & Liao, J. B. Human papillomavirus and cervical cancer. Adv. Virus Res. 66, 125-159 (2006).
17. Bernard, H. U. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir. Ther. 7, 219-237 (2002).
18. Thierry, F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology 384, 375-379 (2009).
19. McBride, A. A. Replication and partitioning of papillomavirus genomes. Adv. Virus Res. 72, 155-205 (2008).
20. Doorbar, J., Ely, S., Sterling, J., McLean, C. & Crawford, L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 352, 824-827 (1991).
21. Moscicki, A. B. et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30 (Suppl. 5), F24-F33 (2012).
22. Schwartz, S. HPV-16 RNA processing. Front. Biosci. 13, 5880-5891 (2008).
23. Zheng, Z. M. & Baker, C. C. Papillomavirus genome structure, expression, and posttranscriptional regulation. Front. Biosci. 11, 2286-2302 (2006).
24. Graham, S. V. Papillomavirus 3′ UTR regulatory elements. Front. Biosci. 13, 5646-5663 (2008).
25. Kozak, M. Regulation of translation inititation in eucaryotic systems. Annu. Rev. Cell Biol. 8, 197-225 (1992).
26. Orru, B., Cunniffe, C., Ryan, F. & Schwartz, S. Development and validation of a novel reporter assay for human papillomavirus type 16 late gene expression. J. Virol. Meth. 183, 106-116 (2012).
27. Zhao, X., Rush, M. & Schwartz, S. Identification of an hnRNP A1 dependent splicing silencer in the HPV-16 L1 coding region that prevents premature expression of the late L1 gene. J. Virol. 78, 10888-10905 (2004).
28. Lambert, P. F. et al. Using an imortalised cell line to study the HPV life cycle in organotypic "raft" cultures. Methods Mol. Med. 11 9, 141-155 (2005).
29. Meyers, C. & Laimins, L. A. In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186, 199-215 (1994).
30. Wang, H. K., Duffy, A. A., Broker, T. R. & Chow, L. T. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 23, 181-194 (2009).
31. Surviladze, Z., Dziduszko, A. & Ozbun, M. A. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. 8, e1002519 (2012).
32. Schiller, J. T., Day, P. M. & Kines, R. C. Current understanding of the mechanism of HPV infection. Gynecol. Oncol. 11 8 (Suppl.1), S12-S17 (2010).
33. Baker, C. & Calef, C. in Human Papillomaviruses 1997: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences (eds Billakanti, S. R., Calef, C. E., Farmer, A. D., Halpern, A. L. & Myers, G. L.) 3-10 (Theoretical Biology and Biophysics, 1997).
34. Doorbar, J. et al. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 178, 254-262 (1990).
35. Grassmann, K., Rapp, B., Maschek, H., Petry, K. U. & Iftner, T. Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. J. Virol. 70, 2339-2349 (1996).
36. Milligan, S. G., Veerapraditsin, T., Ahamet, B., Mole, S. & Graham, S. V. Analysis of novel human papillomavirus type 16 late mRNAs in differentiated W12 cervical epithelial cells. Virology 360, 172-181 (2007).
37. Zheng, Z. M., Tao, M., Yamanegi, K., Bodaghi, S. & Xiao, W. Splicing of a cap-proximal human papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5′ cap. J. Mol. Biol. 337, 1091-1108 (2004).
38. Tang, S., Tao, M., McCoy, J. P. & Zheng, Z.-M. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16-or 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 80, 4249-4263 (2006).
39. Belaguli, N. S., Pater, M. M. & Pater, A. Splice sites of human papillomavirus type 16 E6 gene or heterologous gene required for transformation by E7 and accumulation of E7 RNA. J. Med. Virol. 47, 445-453 (1995).
40. Cheng, S., Schmidt-Grimminger, D.-C., Murant, T., Broker, T. R. & Chow, L. T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9, 2335-2349 (1995).
41. Remm, M., Remm, A. & Ustav, M. Human papillomavirus type 18 E1 protein is translated from polycistronic mRNA by a discontinuous scanning mechanism. J. Virol. 73, 3062-3070 (1999).
42. Stacey, S. N. et al. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J. Virol. 69, 7023-7031 (1995).
43. Filippova, M. et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 81, 4116-4129 (2007).
44. Rosenberger, S., De-Castro Arce, J., Langbein, L., Steenbergen, R. D. M. & Rösl, F. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc. Natl Acad. Sci. USA 107, 7006-7011 (2010).
45. Han, S. P., Tang, Y. H. & Smith, R. Functional diversity of the hnRNPs: past, present and perspectives. Biochem. J. 430, 379-392 (2010).
46. Bodaghi, S., Jia, R. & Zheng, Z. M. Human papillomavirus type 16 E2 and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with suboptimal splice sites. Virology 386, 32-43 (2009).
47. Ajiro, M., Jia, R., Zhang, L., Liu, X. & Zheng, Z. M. Intron definition and a branch site adenosine at nt 385 control RNA splicing of HPV16 E6*I and E7 expression. PLoS ONE 7, e46412 (2012).
48. Lopez-Urrutia, E. et al. A few nucleotide polymorphisms are sufficient to recruit nuclear factors differentially to the intron 1 of HPV-16 intratypic variants. Virus Res. 166, 43-53 (2012).
49. Schmitt, M. et al. Diagnosing cervical cancer and highgrade precursors by HPV-16 transcription patterns. Cancer Res. 70, 249-256 (2010).
50. Rush, M., Zhao, X. & Schwartz, S. A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression. J. Virol. 79, 12002-12015 (2005).
51. Somberg, M. & Schwartz, S. Multiple ASF/SF2 sites in the HPV-16 E4-coding region promote splicing to the most commonly used 3′-splice site on the HPV-16 genome. J. Virol. 84, 8219-8230 (2010).
52. Tranell, A., Fenyö, E. M. & Schwartz, S. Serine-and arginine-rich proteins 55 and 75 (SRp55 and SRp75) induce production of HIV-1 vpr mRNA by inhibiting the 5′-splice site of exon 3. J. Biol. Chem. 285, 31537-31547 (2010).
53. Ozbun, M. A. Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J. Virol. 76, 11291-11300 (2002).
54. Klumpp, D., Stubenrauch, F. & Laimins, L. A. Differential effects of the splice acceptor at nucleotide 3295 of human papillomavirus 31 on stable and transient viral replication. J. Virol. 71, 8186-8194 (1997).
55. Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q. & Krainer, A. R. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31, 3568-3571 (2003).
56. Jia, R. et al. Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J. Virol. 83, 167-180 (2009).
57. Somberg, M. et al. SRp30c activates human papillomavirus type 16 L1 mRNA expression via a bimodal mechanism. J. Gen. Virol. 92, 2411-2421 (2011).
58. Karni, R. et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Struct. Mol. Biol. 14, 185-193 (2007).
59. Fay, J., Kelehan, P., Lambkin, H. & Schwartz, S. Increased expression of cellular RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J. Med. Virol. 81, 897-907 (2009).
60. Mole, S. et al. RNA splicing factors regulated by HPV16 during cervical tumour progression. J. Pathol. 219, 383-391 (2009).
61. Mole, S., Milligan, S. G. & Graham, S. V. Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF. J. Virol. 83, 357-367 (2009).
62. Xue, Y. et al. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res. 70, 5316-5325 (2010).
63. Spink, K. M. & Laimins, L. A. Induction of the human papillomavirus type 31 late promoter requires differentiation but not DNA amplification. J. Virol. 79, 4918-4926 (2005).
64. Deng, W. et al. mRNA splicing regulates human papillomavirus type 11 E1 protein production and DNA replication. J. Virol. 77, 10213-10226 (2003).
65. Mannik, A., Runkorg, K., Jaanson, N., Ustav, M. & Ustav, E. Induction of the bovine papillomavirus origin "onion skin"-type DNA replication at high E1 protein concentrations in vivo. J. Virol. 76, 5835-5845 (2002).
66. Hubert, W. G. & Laimins, L. A. Human papillomavirus type 31 replication modes during the early phases of the viral life cycle depend on transcriptional and posttranscriptional regulation of E1 and E2 expression. J. Virol. 76, 2263-2273 (2002).
67. Fertey, J. et al. Interaction of the papillomavirus E8-E2C protein with the cellular CHD6 protein contributes to transcriptional repression. J. Virol. 84, 9505-9515 (2010).
68. Lace, M. J., Anson, J. R., Thomas, G. S., Turek, L. P. & Haugen, T. H. The E8-E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes. J. Virol. 82, 10841-10853 (2008).
69. Zhao, X. et al. A 57 nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2 and PTB. J. Virol. 79, 4270-4288 (2005).
70. Andrew, E. M. & DiMaio, D. Hierarchy of polyadenylation site usage by bovine papillomavirus in transformed cells. J. Virol. 67, 7705-7710 (1993).
71. Terhune, S. S., Hubert, W. G., Thomas, J. T. & Laimins, L. A. Early polyadenylation signals of human papillomavirus type 31 negatively regulate capsid gene expression. J. Virol. 75, 8147-8157 (2001).
72. Terhune, S. S., Milcarek, C. & Laimins, L. A. Regulation of human papillomavirus 31 polyadenylation during the differentiation-dependent life cycle. J. Virol. 73, 7185-7192 (1999).
73. Kaufmann, I., Martin, G., Friedlein, A., Langen, H. & Keller, W. Human Fip1 is a subunit of CPSF that binds to U-rich elements and stimulates poly(A) polymerase. EMBO J. 23, 616-626 (2004).
74. Lace, M. J. et al. Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs. J. Virol. 83, 11784-11794 (2009).
75. Jeon, S., Allen-Hoffmann, B. L. & Lambert, P. F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69, 2989-2997 (1995).
76. Jeon, S. & Lambert, P. F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl Acad. Sci. USA 92, 1654-1658 (1995).
77. Häfner, N. et al. Integration of the HPV-16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27, 1610-1617 (2008).
78. Tan, W. & Schwartz, S. The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3′ untranslated region. J. Virol. 69, 2932-2945 (1995).
79. Lace, M. J. et al. Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture. J. Virol. 83, 7457-7466 (2009).
80. Oberg, D., Fay, J., Lambkin, H. & Schwartz, S. A downstream polyadenylation element in human papillomavirus type 16 encodes multiple GGG-motifs and interacts with hnRNPH. J. Virol. 79, 9254-9269 (2005).
81. Baker, C. C. & Noe, J. S. Transcriptional termination between bovine papillomavirus type 1 (BPV-1) early and late polyadenylation sites blocks late transcription in BPV-1-transformed cells. J. Virol. 63, 3529-3534 (1989).
82. Kanopka, A., Mühlemann, O. & Akusjärvi, G. Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA. Nature 381, 535-538 (1996).
83. Somberg, M. et al. Adenovirus E4orf4 induces HPV-16 late L1 mRNA production. Virology 383, 279-290 (2009).
84. Johansson, C. et al. HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J. 13, 3212-3227 (2012).
85. Nemeroff, M. E., Barabino, S. M., Li, Y., Keller, W. & Krug, R. M. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3′ end formation of cellular pre-mRNAs. Mol. Cell 1, 991-1000 (1998).
86. Backström Winquist, E. et al. Inefficient splicing of segment 7 and 8 mRNAs is an inherent property of influenza virus A/Brevig Mission/1918/1 (H1N1) that causes elevated expression of NS1 protein. Virology 422, 46-58 (2011).
87. Somberg, M., Zhao, X., Fröhlich, M., Evander, M. & Schwartz, S. PTB induces HPV-16 late gene expression by interfering with splicing inhibitory elements at the major late 5′-splice site SD3632. J. Virol. 82, 3665-3678 (2008).
88. Ozbun, M. A. & Meyers, C. Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J. Virol. 71, 5161-5172 (1997).
89. Tomita, Y. & Simizu, B. Translational properties of the human papillomavirus type-6 L1-coding mRNA. Gene 133, 223-225 (1993).
90. Kanopka, A. et al. Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins. Nature 393, 185-187 (1998).
91. Zhao, X., Fay, J., Lambkin, H. & Schwartz, S. Identification of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology 369, 351-363 (2007).
92. Jacquenet, S. et al. A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Ta t mRNA and binds protein hnRNP H. J. Biol. Chem. 276, 40464-40475 (2001).
93. Zhao, X. & Schwartz, S. Inhibition of HPV-16 L1 expression from L1 cDNAs correlates with the presence of hnRNP A1 binding sites in the L1 coding region. Virus Genes 36, 45-53 (2008).
94. Zhao, X., Rush, M., Carlsson, A. & Schwartz, S. The presence of inhibitory RNA elements in the late 3′-untranslated region is a conserved property of human papillomaviruses. Virus Res. 125, 135-144 (2007).
95. Furth, P. A. & Baker, C. C. An element in the bovine papillomavirus late 3′ untranslated region reduces polyadenylated cytoplasmic RNA levels. J. Virol. 65, 5806-5812 (1991).
96. Kennedy, I. M., Haddow, J. K. & Clements, J. B. Analysis of human papillomavirus type 16 late mRNA 3′ processing signals in vitro and in vivo. J. Virol. 64, 1825-1829 (1990).
97. Kennedy, I. M., Haddow, J. K. & Clements, J. B. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J. Virol. 65, 2093-2097 (1991).
98. Cumming, S. A. et al. The human papillomavirus type 31 untranslated region contains a complex bipartite negative regulatory element. J. Virol. 76, 5993-6003 (2002).
99. Sokolowski, M., Zhao, C., Tan, W. & Schwartz, S. AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors. Oncogene 15, 2303-2319 (1997).
100. Wiklund, L., Sokolowski, M., Carlsson, A., Rush, M. & Schwartz, S. Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability in the HPV-1 late 3′ untranslated region. J. Biol. Chem. 277, 40462-40471 (2002).
101. Sokolowski, M., Furneaux, H. & Schwartz, S. The inhibitory activity of the AU-rich RNA element in the human papillomavirus type 1 late 3′ untranslated region correlates with its affinity for the elav-like HuR protein. J. Virol. 73, 1080-1091 (1999).
102. Sokolowski, M. & Schwartz, S. Heterogeneous nuclear ribonucleoprotein C binds exclusively to the functionally important UUUUU-motifs in the human papillomavirus type-1 AU-rich inhibitory element. Virus Res. 73, 163-175 (2001).
103. Cumming, S. A., Chuen-Im, T., Zhang, J. & Graham, S. V. The RNA stability regulator HuR regulates L1 protein expression in vivo in differentiating cervical epithelial cells. Virology 383, 142-149 (2009).
104. Fan, X. C. & Steitz, J. A. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17, 3448-3460 (1998).
105. Carlsson, A. & Schwartz, S. Inhibitory activity of the human papillomavirus type 1 AU-rich element correlates inversely with the levels of the elav-like HuR protein in the cell cytoplasm. Arch. Virol. 145, 491-503 (2000).
106. Barksdale, S. K. & Baker, C. C. The human immunodeficiency virus type 1 Rev protein and the Rev-responsive element counteract the effect of an inhibitory 5′ splice site in a 3′ untranslated region. Mol. Cell. Biol. 15, 2962-2971 (1995).
107. Tan, W., Felber, B. K., Zolotukhin, A. S., Pavlakis, G. N. & Schwartz, S. Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1. J. Virol. 69, 5607-5620 (1995).
108. McPhillips, M. G. et al. SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells. J. Virol. 78, 10598-10605 (2004).
109. Cheunim, T., Zhang, J., Milligan, S. G., McPhillips, M. G. & Graham, S. V. The alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial cell differentiation and binds the human papillomavirus type 16 late regulatory element. Virus Res. 131, 189-198 (2008).
110. Furth, P. A., Choe, W. T., Rex, J. H., Byrne, J. C. & Baker, C. C. Sequences homologous to 5′ splice sites are required for the inhibitory activity of papillomavirus late 3′ untranslated regions. Mol. Cell. Biol. 14, 5278-5289 (1994).
111. Gunderson, S. I., Polycarpou-Schwarz, M. & Mattaj, I. W. U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Mol. Cell 1, 255-264 (1998).
112. Cumming, S. A., McPhillips, M. G., Veerapraditsin, T., Milligan, S. G. & Graham, S. V. Activity of the human papillomavirus type 16 late negative regulatory element is partly due to four weak consensus 5′ splice sites that bind a U1 snRNP-like complex. J. Virol. 77, 5167-5177 (2003).
113. Goraczniak, R. & Gunderson, S. I. The regulatory element in the 3′ untranslated region of human papillomavirus 16 inhibits expression by binding CUG binding protein 1. J. Biol. Chem. 283, 2286-2296 (2008).
114. Collier, B., Öberg, D., Zhao, X. & Schwartz, S. Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J. Virol. 76, 2739-2752 (2002).
115. Leder, C., Kleinschmidt, J. A., Wiethe, C. & Müller, M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 75, 9201-9209 (2001).
116. Heino, P., Dillner, J. & Schwartz, S. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus like particles. Virology 214, 349-359 (1995).
117. Sokolowski, M., Tan, W., Jellne, M. & Schwartz, S. mRNA instability elements in the human papillomavirus type 16 L2 coding region. J. Virol. 72, 1504-1515 (1998).
118. Mori, S. et al. Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells. Mol. Cell. Biochem. 288, 47-57 (2006).
119. Afonina, E., Neumann, M. & Pavlakis, G. N. Preferential binding of poly(A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA. J. Biol. Chem. 272, 2307-2311 (1997).
120. Zhou, W. et al. Multiple RNA splicing and the presence of cryptic RNA splice donor and acceptor sites may contribute to low expression levels and poor immunogenicity of potential DNA vaccines containing the env gene of equine infectious anemia virus (EIAV). Vet. Microbiol. 88, 127-151 (2002).
121. Berg, M., DiFatta, J., Hoiczyk, E., Schlegel, R. & Ketner, G. Viable adenovirus vaccine prototypes: highlevel production of a papillomavirus capsid antigen from the major late transcription unit. Proc. Natl Acad. Sci. USA 102, 4590-4595 (2005).
122. Oberg, D., Collier, B., Zhao, X. & Schwartz, S. Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J. Virol. 77, 11674-11684 (2003).
123. Rollman, E. et al. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology 322, 182-189 (2004).
124. Kudla, G., Lipinski, L., Caffin, F., Helwak, A. & Zylicz, M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 4, 933-942 (2006).
125. Wang, X. M., Jansen, K. U. & McClements, W. L. DNA replicative functions of highly-expressed, codon-optimized human papillomavirus proteins E1 and E2. J. Virol. Methods 108, 83-90 (2003).
126. Disbrow, G. L., Sunitha, I., Baker, C. C., Hanover, J. & Schlegel, R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 3 11, 105-114 (2003).
127. Lin, C.-T. et al. A DNA vaccine encoding a codon-optimised human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J. Biomed. Sci. 13, 481-488 (2006).
128. Liu, W. J. et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 301, 43-52 (2002).
129. Ser(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. Nucleic Acids Res. 32, 4448-4461 (2004).
130. Zhao, K. N., Gu, W., Fang, N. X., Saunders, N. A. & Frazer, I. H. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol. Cell. Biol. 19, 8643-8655 (2005).
131. Collier, B., Goobar-Larsson, L., Sokolowski, M. & Schwartz, S. Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J. Biol. Chem. 273, 22648-22656 (1998).
132. Cartegni, L., Chew, S. L. & Krainer, A. R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nature Rev. Genet. 3, 285-298 (2002).
133. Chen, M. & Manley, J. L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nature Rev. Mol. Cell Biol. 11, 741-754 (2009).
134. Long, J. C. & Caceres, J. F. The SR protein family of splicing factors: master regulators of gene expression. Biochem. J. 417, 15-27 (2009).
135. Manley, J. L. & Krainer, A. R. A rationale nomenclature for serine/argininge-rich protein splicing factors (SR proteins). Genes Dev. 24, 1073-1074 (2010).
136. MacDonald, C. C. & McMahon, K. W. Tissue-specific mechanisms of alternative polyadenylation: testis, brain, and beyond. Wiley Interdiscip. Rev. RNA 3, 494-501 (2010).
137. Singh, R. K. & Cooper, T. A. Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 18, 472-482 (2012).
138. Keren, H., Lev-Maor, G. & Ast, G. Alternative splicing and evolution: diversification, exon definition and function. Nature Rev. Genet. 11, 345-355 (2010).
139. Stolzfus, C. M. & Madsen, J. M. Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr. HIV Res. 1, 43-55 (2006).
140. Zheng, Z. M. Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression. J. Biomed. Sci. 11, 278-294 (2004).